CDT Equity

CDT Equity Debt

The Debt of CDT Equity (CDT) as of Nov 6, 2026 is 1.29 B USD. In the previous year, Debt was 7.46 M USD — a change of 17,141.06% (higher).

Debt

1.29 BUSD

YoY

17,141.06%

Last updated:

In 2025, CDT Equity's total debt was 1.29 B USD, a 17,141.06% change from the 7.46 M USD total debt recorded in the previous year.

The CDT Equity Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2021
177,057.00 USD
Jan 1, 2022
2.01 M USD
Jan 1, 2023
985,000.00 USD
Jan 1, 2024
7.46 M USD
Jan 1, 2025
1.29 B USD
The CDT Equity Debt history
YEARDebtYoY
1.29 BUSD+17,141.06%
7.46 MUSD+657.06%
985,000.00USD-51.00%
2.01 MUSD+1,035.23%
177,057.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

CDT Equity Stock analysis

What does CDT Equity do? CDT Equity Inc generates revenue through the development and commercialization of clinical assets targeting unmet medical needs. The company focuses on disease-agnostic life science solutions, with key assets including AZD1656, a glucokinase activator for diabetes mellitus and Hashimoto’s Thyroiditis treatment, and AZD5904, a myeloperoxidase inhibitor for idiopathic male infertility. These assets are licensed for use in autoimmune diseases, immunodeficient conditions, and specific medical applications like uveitis, preterm labor, and renal transplant rejection. Pharmaceutical companies and healthcare providers purchase these clinical assets for research and therapeutic development. The company’s revenue streams derive from licensing agreements and commercial partnerships for its pipeline products. AZD1656 is positioned as a treatment option for Hashimoto’s Thyroiditis and Graves’ disease, while AZD5904 targets idiopathic male infertility. The firm’s focus on autoimmune and immunodeficient conditions aligns with healthcare providers seeking innovative therapies for complex patient populations. Licensing deals with pharmaceutical firms drive the primary revenue model. CDT Equity Inc’s business model centers on developing and licensing clinical assets across multiple therapeutic areas. Its pipeline includes AZD1656 for diabetes and thyroid conditions, and AZD5904 for infertility and autoimmune disorders. The company collaborates with healthcare providers and pharmaceutical partners to advance these assets toward commercialization, generating income through licensing fees and future product sales. CDT Equity is one of the most popular companies on Eulerpool.

Debt Details

Understanding CDT Equity's Debt Structure

CDT Equity's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing CDT Equity's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to CDT Equity’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in CDT Equity’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about CDT Equity stock

Debt of CDT Equity is 1.29 B USD in 2025.

Debt of CDT Equity changed from 7.46 M USD to 1.29 B USD, representing a 17,141.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt CDT Equity since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's CDT Equity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — CDT Equity

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — CDT Equity